secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001437749-23-009184
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics appoints Erick Lucera, former AVEO CFO, to Board of Directors
--------------------------------------------------------------------------------

- Erick Lucera appointed to SAB Biotherapeutics Board effective April 4, 2023; term until next annual meeting.
- Lucera most recently served as CFO of AVEO Oncology through its acquisition by LG Chem; prior CFO at Valeritas and Viventia Bio.
- With 30+ years in biotech/med device finance, he brings experience in corporate finance, M&A, and public offerings.
- Compensation consistent with other non-employee directors as described in the 2022 proxy statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923009184/0001437749-23-009184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923009184/sabs20230403_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-009184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer